Last reviewed · How we verify
MED2005
MED2005 is a topical cream formulation designed to enhance erectile function through local application to penile tissue.
MED2005 is a topical cream formulation designed to enhance erectile function through local application to penile tissue. Used for Erectile dysfunction.
At a glance
| Generic name | MED2005 |
|---|---|
| Also known as | Glyceryl Trinitrate, glyceryl trinitrate |
| Sponsor | Futura Medical Developments Ltd. |
| Drug class | Topical phosphodiesterase inhibitor or vasodilator |
| Modality | Small molecule |
| Therapeutic area | Urology / Sexual Health |
| Phase | Phase 3 |
Mechanism of action
MED2005 is a proprietary topical formulation developed by Futura Medical for the treatment of erectile dysfunction. The exact molecular mechanism has not been publicly disclosed in detail, but topical ED therapies typically work by promoting vasodilation and increasing blood flow to penile tissue through local absorption. The drug is being evaluated in Phase 3 clinical trials for this indication.
Approved indications
- Erectile dysfunction
Common side effects
- Local skin irritation or erythema
- Penile pain or discomfort
- Headache
Key clinical trials
- Clinical Trial Using Topically Applied Glyceryl Trinitrate (GTN) for the Treatment of Erectile Dysfunction (PHASE3)
- Clinical Trial of Topically-applied Glyceryl Trinitrate (GTN) for the Treatment of Erectile Dysfunction (ED) (PHASE2)
- Evaluating MED2005 & Nitrostat Bioavailability (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MED2005 CI brief — competitive landscape report
- MED2005 updates RSS · CI watch RSS
- Futura Medical Developments Ltd. portfolio CI